Drug Overview
Stiolto Respimat ([olodaterol + tiotropium]; Boehringer Ingelheim) is a fixed-dose combination of the long-acting beta 2 agonist (LABA) olodaterol and the gold-standard long-acting muscarinic antagonist (LAMA) tiotropium. The LABA/LAMA combination received US and EU approvals for use in chronic obstructive pulmonary disease (COPD) in Q2 2015.
The author forecastsStiolto Respimat to capture significant share in the COPD market and drive sales in the LABA/LAMA class. This is based on the drug’s promising efficacy data to date and Boehringer Ingelheim’s strong marketing capabilities and extensive experience in the respiratory market as a result of its well-established LAMA, Spiriva (tiotropium). Boehringer Ingelheim is expected to invest heavily to encourage patient switching from Spiriva to Stiolto Respimat in an attempt to protect its respiratory franchise and minimize competition from the numerous LABA/LAMAs and triple-combination therapies that are reaching the COPD market.
Stiolto Respimat ([olodaterol + tiotropium]; Boehringer Ingelheim) is a fixed-dose combination of the long-acting beta 2 agonist (LABA) olodaterol and the gold-standard long-acting muscarinic antagonist (LAMA) tiotropium. The LABA/LAMA combination received US and EU approvals for use in chronic obstructive pulmonary disease (COPD) in Q2 2015.
The author forecastsStiolto Respimat to capture significant share in the COPD market and drive sales in the LABA/LAMA class. This is based on the drug’s promising efficacy data to date and Boehringer Ingelheim’s strong marketing capabilities and extensive experience in the respiratory market as a result of its well-established LAMA, Spiriva (tiotropium). Boehringer Ingelheim is expected to invest heavily to encourage patient switching from Spiriva to Stiolto Respimat in an attempt to protect its respiratory franchise and minimize competition from the numerous LABA/LAMAs and triple-combination therapies that are reaching the COPD market.
Table of Contents
OVERVIEW
LIST OF FIGURES
LIST OF TABLES
